TCT 2023 Late-Breaking Science Collection
Published: 09 January 2024
-
Views:
319
-
Likes:
7
-
Views:
319
-
Likes:
7
-
25m 48sPart 1 | Session 1 View from the Thoraxcenter: TCT 23 Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
30m 36sPart 1 | Session 2 View from the Thoraxcenter: TCT 23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
8m 13sPart 2 | Session 1 5 Trials That Will Change My Practice With Dr Kendra Grubb Kendra J Grubb
-
14m 10sPart 2 | Session 2 5 Trials That Will Change My Practice With Dr Mirvat Alasnag Mirvat Alasnag
-
12m 36sPart 2 | Session 3 5 Trials That Will Change My Practice With Dr Bernardo Cortese Bernardo Cortese
-
7m 42sPart 3 | Session 1 5Y Outcomes From the PARTNER 3 Low-Risk Trial
-
6m 43sPart 3 | Session 2 AGENT IDE: AGENT Paclitaxel Coated Balloon Angioplasty for In-Stent Restenosis Robert Yeh
-
8m 46sPart 3 | Session 3 Four-Year Outcomes from the EVOLUT Low Risk Trial Michael J Reardon
-
11m 22sPart 3 | Session 4 PICSO-AMI-I: Pressure Controlled Intermittent Coronary Sinus Occlusion in Acute Myocardial Infarction Giovanni Luigi Di Maria
Overview
Stay up-to-date with our regular review series, View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL). In this #TCT2023 edition they provide a short analysis of the most pertinent data from the late-breaking science presentations.
Short, accessible Expert Interviews were conducted with investigators focusing on study design, key results and applicability of the latest data.
More from this programme
Part 1
View from the Thoraxcenter
Part 2
Highlights
Part 3
Interviews
About the episode
TCT 23 - We are joined by Dr Samir Kapadia (Cleveland Clinic, Cleveland, OH) to discuss the findings of the WATCH-TAVR Trial (NCT03173534).
WATCH-TAVR aimed to evaluate the safety and effectiveness of left atrial appendage occlusion with the WATCHMAN device to prevent stroke and bleeding in patients with atrial fibrillation (AF) who are undergoing transcatheter aortic valve replacement (TAVR). This is a prospective, multicenter, randomized trial, with 32 centers in the United States. 350 patients were enrolled, with 175 randomized to receive TAVR with medical therapy, and 175 to receive TAVR and WATCHMAN.
Results showed that LAAO with the WATCHMAN 2.5 device at the time of TAVR is non-inferior to contemporary medical therapy for the composite endpoint of all-cause mortality, stroke and major bleeding at 2 years in patients with atrial fibrillation and severe asymptomatic aortic stenosis. In-hospital mortality was low (0.6%) in both groups with similar length of stay.
Interview Questions:
- What was the reasoning behind this trial?
- Could you tell us about the WATCHMAN device?
- What was the patient population and study design?
- What are the key findings?
- What are your take-home messages?
- What further study is still required, and what are the next steps?
Recorded remotely from Cleveland, 2023.
Editor: Jordan Rance
Video Specialist: Tom Green
Comments